Home・Elenco Azioni・Genmab A-S

Genmab A-S

Chiusa

2,121 -1.85

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2094

Massimo

2161

Metriche Chiave
By Trading Economics
Entrata	243M 295M
Vendite	259M 1.2B
P/E Media del settore	26.113 57.366
EPS	34.85
Margine di Profitto	25.541
Dipendenti	3,119
EBITDA	216M 431M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	-1.49% downside

Dividendi
By Acuity
Utili prossimi	5 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	16B 130B
Apertura precedente	2122.85
Chiusura precedente	2121

Genmab A-S Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 ago 2026, 23:56 UTC

News

Array Technologies has acquired Affordable Wire Management, enhancing its portfolio and growth potential. Shares are trading slightly higher in after-market hours.

31 ago 2026, 23:56 UTC

MannKind Corp shares are lower in after-market trading, continuing a trend observed over the past four sessions amid rising oil prices and inflation concerns.

31 ago 2026, 23:56 UTC

Correlated Moves

Regal Rexnord Corp shares are higher in after-market trading, reflecting a cumulative return of 0.44% since Monday's close amid similar trends from Eaton Corporation PLC.

31 ago 2026, 23:56 UTC

Schrodinger Inc shares are higher in after-hours trading, influenced by rising oil prices and inflation concerns ahead of the Federal Reserve meeting.

31 ago 2026, 23:56 UTC

Mosaic Co's shares are lower in after-market hours, reflecting inflation concerns from rising oil prices ahead of the Federal Reserve meeting.

31 ago 2026, 23:56 UTC

TransDigm Group Inc shares are lower in after-market hours. No specific news was identified to explain the decline amid overall weak market performance.

31 ago 2026, 23:56 UTC

News

Frontier Group Holdings plans to terminate leases for 13 A320neo aircraft, leading to anticipated charges of $60 million to $80 million. Shares are lower in after-market hours.

31 ago 2026, 23:56 UTC

Exelon Corp shares are lower in after-market trading, following fluctuations since Monday's close. Rising oil prices and inflation concerns influence broader market sentiment.

31 ago 2026, 23:56 UTC

Shell PLC shares are lower in after-market trading, following a slight decline since Monday's close. Oil prices have risen, impacting broader market sentiment.

31 ago 2026, 23:56 UTC

abrdn Physical Palladium Shares ETF traded roughly flat after-market hours, with no specific news identified. Global equity indices are mixed amid inflation concerns.

31 ago 2026, 23:52 UTC

Japan's Q2 2026 Capital Spending YoY forecasted to rise only 0.2%, signaling subdued private investment growth amid cautious market sentiment.

31 ago 2026, 23:52 UTC

South Korea's S&P Global Manufacturing PMI release on September 1 faces cautious market sentiment amid rising oil prices and inflation concerns.

31 ago 2026, 23:52 UTC

Federal Reserve Chair Kevin Warsh's hawkish remarks boost interest rate hike expectations to 60-65% amid rising inflation concerns and geopolitical tensions.

31 ago 2026, 23:52 UTC

ISM Manufacturing Employment Data Release on September 1, 2026, Sparks Caution Amid Inflation Concerns and Fed Rate Hike Speculation.

31 ago 2026, 23:52 UTC

ISM Manufacturing PMI Release on September 1 Expected to Show Continued Growth Amid Geopolitical Tensions and Fed Rate Hike Speculation.

31 ago 2026, 23:52 UTC

Australia's Balance of Trade data set for September 3, 2026, anticipates a AUD 1.4 billion surplus amid mixed market sentiment and geopolitical tensions affecting investor confidence.

31 ago 2026, 23:52 UTC

JOLTs Job Openings Report on September 1 Expected to Influence Fed Rate Hike Decisions Amid Geopolitical Tensions and Inflation Concerns.

31 ago 2026, 23:52 UTC

U.S. Initial Jobless Claims Expected at 205K Amid Inflation Concerns and Fed Rate Hike Speculation

31 ago 2026, 23:52 UTC

Japan's Q2 2026 GDP Growth Rate Expected at 0.3%, Sparking Speculation of Interest Rate Hike Amid Mixed Economic Sentiment

31 ago 2026, 23:52 UTC

Japan's Q2 2026 GDP Growth Release Expected at 1.1% Amid Mixed Economic Signals and Potential BoJ Interest Rate Hikes

31 ago 2026, 23:51 UTC

Enterprise Financial Services Corp shares are lower in after-market trading, lacking any specific news to explain the decline. The stock remains below its 20-day moving average.

31 ago 2026, 23:51 UTC

Dyadic International Inc shares are higher in after-market hours, showing strong buying interest despite a recent significant decline and downward pressure over the past sessions.

31 ago 2026, 23:51 UTC

Wayfair Inc shares are lower in after-market trading, reversing a trend of higher daily closes. No specific news was identified to explain the decline.

31 ago 2026, 23:51 UTC

United Parks & Resorts Inc. shares are higher in after-market trading, reflecting notable strength despite no specific company news identified.

31 ago 2026, 23:51 UTC

Playtika Holding Corp shares are higher in after-market trading. No specific news was identified to explain this movement amid broader market volatility.

31 ago 2026, 23:51 UTC

European equity markets decline amid rising oil prices and inflation concerns following U.S.-Iran military tensions, with investors cautious ahead of key economic data.

31 ago 2026, 23:51 UTC

U.S. equity indices decline amid rising oil prices and geopolitical tensions, with Fed rate hike expectations intensifying.

31 ago 2026, 23:51 UTC

Asia equity markets mixed as Middle East tensions and hawkish Fed signals drive oil prices up and investor caution.

31 ago 2026, 23:51 UTC

U.S. and European markets decline amid rising oil prices and inflation fears following U.S.-Iran tensions, while Dallas Fed Manufacturing Index signals strong recovery.

31 ago 2026, 23:51 UTC

Helmerich and Payne Inc. shares are higher in after-market trading, supported by a rise in Brent crude futures amid geopolitical tensions in the Strait of Hormuz.

Confronto tra pari

Modifica del prezzo

Genmab A-S Previsione

Obiettivo di Prezzo

By TipRanks

-1.49% in calo

Previsioni per 12 mesi

Media 2,493.35 DKK -1.49%

Alto 3,320 DKK

Basso 308.417 DKK

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Genmab A-S - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

7 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Genmab A-S - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.